CA-NETAPP
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it has expanded its relationship with Porsche Motorsport to become the exclusive Intelligent Data Infrastructure partner, accelerating access to Porsche Motorsport’s data to drive strategic decision-making on the track. This expansion also creates a new relationship between NetApp and Team Porsche Penske Motorsport in the IMSA WeatherTech SportsCar Championship (IWSC) and World Endurance Championship (WEC), as well as continued support for the TAG Heuer Porsche Formula E Team.
While working with NetApp, the TAG Heuer Porsche Formula E Team has earned four victories in the 2023-2024 Formula E season, putting the team in a competitive position for the season. NetApp’s approach to racing data, via its intelligent data infrastructure, gives the Formula E team real-time access to the data Porsche needs to inform race strategy, support data-driven decision making, and improve outcomes. For example, data-driven simulations help the team pick the best moment to activate the team’s signature Formula E Attack Mode, which unlocks an additional 50 kilowatts of engine power for a well-timed burst of extra speed. With the expanded partnership, Team Porsche Penske Motorsport will leverage NetApp technology in North America to share and analyze the data it needs to drive similar complex decisions in the IWSC and WEC.
“Racing is the ultimate test for technology because speed is literally the name of the game. Only a data infrastructure that’s intelligent can deliver data fast enough to help motorsports teams earn a victory lap,” said Gabie Boko, Chief Marketing Officer at NetApp. “Motorsports generate massive amounts of data during and even before a race that helps them develop their race strategy and respond to changing conditions. The Porsche Motorsport teams need reliable and instantaneous access to their data to stay competitive. As the leader in unified data storage, NetApp is uniquely positioned to help Porsche Motorsport share and analyze its data across its complex and high-performance IT environment wherever and whenever they need it, from the garage to the track.”
With this partnership, Porsche Motorsport can access its data in real time, supporting driver and team performance by leveraging NetApp’s market-leading capabilities, including:
- Cloud Volumes ONTAP: This offering creates a consistent storage experience for Porsche Motorsport across its hybrid cloud environment, allowing all of the team’s data to be consolidated in the cloud, but accessed anywhere it is needed.
- BlueXP: Porsche Motorsport uses this software to create a single control plane for managing its data across its hybrid cloud environment, including the capability to create local copies of datasets to conduct low-latency analysis for real-time, trackside decision making.
- Cloud Backup: Using this capability protects the significant investment of time, money, and expertise Porsche Motorsport has put into creating its data by ensuring high availability and cyber resiliency.
“Motorsports are more about technology than almost anything else. A skilled driver is only as good as the vehicle and race strategy can empower them to be,” said Carlo Wiggers, Director Team Management, Business Relations, and Esports at Porsche Motorsport. “NetApp helps us shine by powering the intelligent data infrastructure that moves our data to the exact place where it will be the most useful. Our teams travel around the world for race events but still need a connection to the data generated by our home base in Germany. NetApp has proven time and again that it can deliver that data reliably and speedily, giving us the confidence to expand our partnership to include the IWSC and WEC events in North America.”
Additional Resource
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604479993/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
